Natco Pharma rolls out additional strengths for generic version of Revlimid in US
Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.
Hyderabad: Natco Pharma Limited has announced the launch of additional strengths for the generic version of Revlimid (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the United States, through its marketing partner Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.With this launch the companies made available all the strengths of lenalidomide in...
Hyderabad: Natco Pharma Limited has announced the launch of additional strengths for the generic version of Revlimid (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the United States, through its marketing partner Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.
With this launch the companies made available all the strengths of lenalidomide in the US market.
Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.
Revlimid is a registered trademark of Celgene Corporation, a Bristol-Myers Squibb Company.
Medical Dialogues team had earlier reported that Natco Pharma Limited had launched Pomalidomide Capsules in Canada, the first generic alternative to POMALYST brand in the country approved by Health Canada. Pomalidomide is used in combination with Dexamethasone and Bortezomib for the treatment of adult patients with multiple myeloma.
Read also: Multiple Myeloma medicine: Natco Pharma unveils Pomalidomide under brand NAT-POMALIDOMIDE in Canada
Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations (“FDF”) and active pharmaceutical ingredients (“APIs”). The company's focus is primarily on niche therapeutic areas and complex products. It markets and distributes products in over 40 countries. It sells FDF products in the United States, India, Europe and the rest of the world (“RoW”). Natco also operates in certain key geographies through its subsidiaries.
The company manufactures API products which are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe and USA. In the API segment, it has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides.
Natco Pharma is also engaged in contract manufacturing business, whereby it undertakes selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products.
Read also: Natco Pharma announces submission of ANDA with USFDA for generic version of Olaparib Tablets
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd